MTE #40 Metabolic Dysfunction-Associated Steatohepatitis Therapeutic Agents: What Is Available and What Is Next in Line?

Nov 10 2025
Convention Center: Room 154, Level 1
12:45 PM - 1:30 PM
Ticketed Event

World Class Speakers

Mazen Noureddin, MD, MHSc
Discussion Leader

Mazen Noureddin, MD, MHSc

Houston Methodist Hospital
Mary Rinella, MD, FAASLD
Discussion Leader

Mary Rinella, MD, FAASLD

The University of Chicago

Description

This session focuses on the nuances of selection of therapies for MASH and metabolic complications. Topics include the experience garnered following the US Food and Drug Administration approval of resmetirom and new therapeutic agents currently in phase 3 clinical trials. 

Journey Maps

Objectives

  • Describe the therapeutic choices for MASH and metabolic dysfunction-associated diseases.
  • Recognize the experimental therapies in late-stage clinical trials for MASH.